Cipla, DNDi to launch new malaria drug

New Delhi: Drug firm Cipla on Tuesday said it plans to launch fixed-dose combination anti-malarial drug in India in partnership with non-profit organisation, Drugs for Neglected Diseases Initiative (DNDi).

The company said it has collaborated with DNDi to launch fixed-dose combination of Artesunate (AS) and Mefloquine (MQ) to treat malaria caused by microorganism `P falciparum`.

"This new fixed-dose combination treatment will be introduced in India under the brand name `Mefliam Plus`. The product will be launched in India and Malaysia soon where it has already been registered," Cipla said.

It, however, did not specify the timeline of the launch. The drugs for the fixed-dose combination (ASMQ) are being manufactured in Cipla`s manufacturing unit in Patalganga, which is approved by WHO-Geneva, USFDA, MHRA-UK and various other regulatory bodies, it said.

"This reinforces Cipla`s commitment and its promise `None shall be denied` by making medicines accessible for neglected diseases like malaria," Cipla Chairman and Managing Director Y K Hamied said.

The combination of AS and MQ is proven to be a safe, rapid and reliably effective treatment for uncomplicated P falciparum malaria and is recommended by the World Health Organisation, the company said.

"Clinical efficacy of this fixed-dose combination has been established in various countries including India," it added.

According to the company estimates, there were an estimated 216 million cases of malaria globally in 2010.

"Having ASMQ available for Southeast Asian patients in need is the result of technology transfer from Farmanguinhos in Brazil to Cipla in India," DNDi Executive Director of the Drugs for Neglected Diseases Bernard Pecoul said.

He added that DNDi has successfully collaborated with Cipla since 2008 to develop a fixed-dose combination therapy for malaria in ASEAN countries.

DNDi is a not-for-profit research and development organisation working to deliver new treatments for neglected diseases.


By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link